Loading
NASDAQTechnologySoftware - Application
Latest quote
$26.39
−$0.90 · -3.30%
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Regular session
$26.97
+$0.58 · +2.20%
Regular session · ET · Market data may be delayed.
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Day range
Current $26.97
52-week range
Current $26.97
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
47
Fair Value
Sentiment
51
Mixed
Risk
61
High Risk
Momentum
54
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Day range
Current $26.97
52-week range
Current $26.97
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 255.87M USD | 207.54M USD | 216.67M USD | 180.96M USD | 137.93M USD |
| Cost of goods sold | 113.26M USD | 75.46M USD | 75.97M USD | 79.93M USD | 72.31M USD |
| Gross profit | 142.61M USD | 132.08M USD | 140.69M USD | 101.02M USD | 65.62M USD |
| Research and development | 173.14M USD | 201.79M USD | 181.77M USD | 126.37M USD | 90.9M USD |
| Selling, general, and administrative | 136.37M USD | 139.59M USD | 136.37M USD | 121.47M USD | 86.16M USD |
| Operating expenses | 309.51M USD | 341.38M USD | 318.14M USD | 247.84M USD | 177.06M USD |
| Interest income | — | — | — | 3.95M USD | 1.06M USD |
| Interest expense | — | — | — | 3K USD | — |
| Depreciation and amortization | 6.02M USD | 6.16M USD | 5.55M USD | 4.34M USD | 2.85M USD |
| Operating income | −166.9M USD | −209.3M USD | −177.45M USD | −146.82M USD | −111.44M USD |
| Net income | −103.27M USD | −187.12M USD | 40.72M USD | −149.19M USD | −100.39M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$19.00
29.55% downsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR89.98M0.09%102.88B USD0.06%$137.54+0.17%
ARK Genomic Revolution ETFARKG59.26M2.89%1.56B USD0.75%$50.38+2.21%
iShares Russell 2000 ETFIWM40.41M0.05%77.7B USD0.19%$278.5+0.34%
Vanguard Morningstar Total Stock Market ETFVTI38.32M0.00%2.3T USD0.03%$380.95+0.37%
Vanguard Morningstar Small-Cap ETFVB27.86M0.01%185.3B USD0.03%$288.74+0.38%
Vanguard Morningstar Small-Cap Growth ETFVBK16.01M0.04%44.7B USD0.05%$343.24+0.78%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM14.56M0.09%15.8B USD0.03%$53.46+0.19%
iShares Russell 2000 Growth ETFIWO14.1M0.10%14.04B USD0.24%$355.31+0.52%iShares Core S&P Small-Cap ETFIJRARK Genomic Revolution ETFARKGiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMiShares Russell 2000 Growth ETFIWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
